TScan Therapeutics, Inc.
Clinical trials sponsored by TScan Therapeutics, Inc., explained in plain language.
A clinical-stage biotech developing T-cell receptor therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Custom immune cells take on multiple cancers in early trial Results expected Dec 2026 (estimated)
-
Custom immune cells take on multiple cancers in early trial
Disease control OngoingThis early-stage study tests a new treatment called T-Plex for people with advanced solid tumors (like head and neck, cervical, or melanoma) that haven't responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and…
Phase 1 • Sponsor: TScan Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New screening could open door to T-Cell therapy for Hard-to-Treat cancers
Knowledge-focused OngoingThis study screens up to 1,150 people with advanced solid tumors like head and neck, cervical, or lung cancer. Researchers test blood and tumor samples to see if participants have the right genetic markers for future T-cell therapy trials. The goal is to find who might benefit fr…
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC